NCT05598125 (ECIG-8) is a clinical trial of electronic cigarette (e-cigarette) in Endothelial Function, sponsored by GWT-TUD GmbH.

Who is sponsoring NCT05598125?

NCT05598125 is sponsored by GWT-TUD GmbH.

What drugs are being tested in NCT05598125?

Interventions in NCT05598125: electronic cigarette (e-cigarette), conventional tobacco cigarette.

What condition does NCT05598125 study?

NCT05598125 studies Endothelial Function.

Is NCT05598125 still recruiting?

NCT05598125 is currently terminated. Last updated 28 October 2022.

Last reviewed 2022-10-28 · How we verify

NCT05598125: ECIG-8

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Vascular Function Before vs After Smoking an E-cigarette as Compared to a Normal Cigarette

Terminated Last updated 28 October 2022

What this trial tests

trial testing electronic cigarette (e-cigarette) in Endothelial Function in 64 participants. Terminated before completion.

Timeline

9 January 2017

Primary endpoint
30 July 2019

30 July 2019

Quick facts

Lead sponsor	GWT-TUD GmbH
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	64
Start date	9 January 2017
Primary completion	30 July 2019
Estimated completion	30 July 2019

Drugs / interventions tested

electronic cigarette (e-cigarette)
conventional tobacco cigarette

Conditions studied

Endothelial Function — all drugs for Endothelial Function →

Sponsor

GWT-TUD GmbH — full company profile →

Who can join

Adults 22 to 35, male only, with Endothelial Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation of the effect of one-time use of an electronic e-cigarette in comparison to smoking a conventional cigarette on in vivo conduit endothelial function in healthy long-term smokers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endothelial Function

Currently open trials in the same condition.

NCT06288828 — The Efficacy of Aerobic Exercise Training on Autonomic Nervous System and Endothelial Function in Patients with Compensa · NA · active not recruiting

Other GWT-TUD GmbH trials

Trials by the same sponsor.

NCT05181592 — Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. · Phase 3 · active not recruiting
NCT04833114 — Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line · Phase 3 · active not recruiting
NCT04188639 — Emicizumab in Acquired Hemophilia A · Phase 2 · completed
NCT04257448 — Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From · Phase 1, PHASE2 · completed
NCT04121507 — ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05598125 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GWT-TUD GmbH
Last refreshed: 28 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05598125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing